« Back
Home /
PF-3758309

PF-3758309

Item no.	HY-13007-10mg
Manufacturer	MedChem Express
CASRN	898044-15-0
Amount	10 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Category	Neuroscience Targets for Rodent Neurosciences Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.84
Formula	C25H30N8OS
Citations	[1]Murray, Brion W., et al. Small-molecule p21-activated kinase inhibitor PF3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proceedings of the National Academy of Sciences of the United States of America (2010), 107(20), 9446-9451, S94<br/>[2]Zhao ZS, et al. Do PAKs make good drug targets? F1000 Biol Rep. 2010 Sep 23;2:70.<br/>[3]Ryu BJ, et al. PF-3758309, p21-activated kinase 4 inhibitor, suppresses migration and invasion of A549 human lung cancer cells via regulation of CREB, NF-κB, and β-catenin signalings. Mol Cell Biochem. 2014 Apr;389(1-2):69-77.<br/>[4]Pitts TM, et al. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol. 2013 Mar 28;4:35.
Smiles	CC1=NC2=C(SC=C2)C(NC3=NNC4=C3CN(C(N[C@@H](C5=CC=CC=C5)CN(C)C)=O)C4(C)C)=N1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PF-03758309
Available
Product Description	PF-3758309 (PF-03758309) is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation[1][2][3].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	490.62
Clinical Information	Phase 1
Manufacturers Research Area	Cancer
Solubility	DMSO : ≥ 100 mg/mL
Target	Apoptosis; PAK
Manufacturers Target	Apoptosis; PAK
Isoform	PAK1; PAK2; PAK3; PAK4; PAK5; PAK6
Manufacturers Pathway	Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13007-10mg-safety-datasheet.pdf